Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
Authors
Keywords
-
Journal
Cells
Volume 8, Issue 8, Pages 860
Publisher
MDPI AG
Online
2019-08-09
DOI
10.3390/cells8080860
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TALAPRO-2: A two-part, placebo-controlled phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).
- (2019) Neeraj Agarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on greater than or equal to one novel hormonal therapy (NHT).
- (2019) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.
- (2019) Matthew Raymond Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
- (2019) Evan Y. Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2.
- (2019) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- A PET imaging agent for evaluating PARP-1 expression in ovarian cancer
- (2018) Mehran Makvandi et al. JOURNAL OF CLINICAL INVESTIGATION
- TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
- (2018) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
- (2018) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Noel Clarke et al. LANCET ONCOLOGY
- Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.
- (2018) Nadine M. Tung et al. JOURNAL OF CLINICAL ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- 793PDPreliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations
- (2018) W Abida et al. ANNALS OF ONCOLOGY
- Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
- (2018) Michael Friedlander et al. BRITISH JOURNAL OF CANCER
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
- (2018) Fatima Karzai et al. Journal for ImmunoTherapy of Cancer
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
- (2018) Roman M. Chabanon et al. JOURNAL OF CLINICAL INVESTIGATION
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).
- (2015) Shalu Pahuja et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
- (2014) Maha Hussain et al. INVESTIGATIONAL NEW DRUGS
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
- (2013) A. Min et al. MOLECULAR CANCER THERAPEUTICS
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Dual Roles of PARP-1 Promote Cancer Growth and Progression
- (2012) M. J. Schiewer et al. Cancer Discovery
- Synthetic lethality: exploiting the addiction of cancer to DNA repair
- (2011) M. Shaheen et al. BLOOD
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
- (2011) J. Chad Brenner et al. CANCER CELL
- The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
- (2010) V. J. Weston et al. BLOOD
- Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination
- (2010) Rémi Buisson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started